
CHARACTERISTICS

NAV share I/R as of 09/30/25 3524.57€ / 199.51€ LU0272991307 / LU1120754533 ISIN share I/R Bloomberg code PLACPHE LX / PLACERU LX Investment's horizon >5 years advised Benchmark Eurostoxx Small NR Daily cut-off at 12am (D) Valorisation Management fees 1.40%/2.25% max share I/R 20% TTC of the outperformance Performance fee vs Eurostoxx Small NR Custodian Banque Degroof Luxembourg Management company MC Square



Level of risk (SRI): 4/7 ___

Delegated manager

Legal form

SFDR



	1M	YTD	2024	2023	2022	2021	Since 2021
Abacus Discovery I	-1.5%	+23.2%	+7.8%	+12.4%	-26.4%	+36.8%	+50.1%
MSCI Europe ex-UK Micro NR	+0.2%	+20.1%	-1.3%	-2.3%	-25.5%	+21.9%	+5.1%
EuroStoxx Small NR	+0.0%	+14.5%	-3.5%	+13.9%	-15.5%	+21.8%	+29.5%

	Volatility	Beta 3Y	Sharpe	Number of	Market Cap	EV/EBITDA	P/E	
	3Y		Ratio 3Y	lines	mean (M€)	2025 med.	2025 med.	
Abacus Discovery I	9.4%	0.34	1.26	52	295	7.1x	12.5x	
MSCI Europe ex-UK Micro NR	10.3%	0.59	0.43	1 102	101	N/S	N/S	
EuroStoxx Small NR	15.1%	1.00	0.61	98	6 814	8.7x	13.5x	

FUND MANAGER'S COMMENT

European indices started September lower, with a sharp increase in long-term European bond yields leading to a decline in equity markets. The 30-year German, French, and UK yields reached their highest levels in 14, 16, and 27 years respectively, particularly impacting the small-cap segment, which is more sensitive to such movements. However, the ECB's decision to maintain rates and its projections of stable growth and controlled inflation reassured investors.

As a result, small caps underperformed over the month, with the MSCI Europe ex-UK Micro NR up +0.2% and the Eurostoxx Small NR flat (+0.0%), compared to the Stoxx Europe 600 ex-UK NR up +1.7%. In this context, Abacus Discovery I posted a -1.5% performance for the month, penalized by market conditions and one of our main holdings (Intellego), which proved particularly volatile. This underperformance follows seven consecutive months of outperformance relative to its benchmark. The fund remains in the 1st decile of its category over 5 years on Quantalys and has earned its fifth star this month.

During September, 28 portfolio companies published or detailed their results and outlook. This includes our three main positive and negative contributors for the month. Intellego (3.6% of the portfolio) fell -27% (a -1.3 pt contribution) after a +400% YTD performance as of end-August. Alongside the upward revision of its guidance, "short" reports written by individual investors raised questions among market participants, which we addressed through a direct meeting with the company's management. Altea Green Power (3.2%) and STEF (2.7%) also reported disappointing results, contributing -0.9 pt to performance. Conversely, Arteche (5.8%), the fund's largest position, continued to perform strongly, gaining +27% over the month (+1.4 pt), driven by profitability being one year ahead of its plan, which could prompt a revision of its short-term strategic plan.

At the portfolio level, we took advantage of the decline in certain stocks such as B&C Speakers, SDI Group, Séché, and Journeo to increase our positions. Similarly, we took some profits on Arteche, CICOR, and Intellego (before the drop) following their excellent performances since the start of the year.

ABACUS PROCESS

Quality Company

- Economic resilience
- Sustainable growth
- Durable profitability
- Competitive advantages
- Exemplary governance

Undervalued

- Disciplined valuation
- · Rigorous fundamental analysis
- Underappreciated opportunities

Long term approach

- Investment horizon: 5-10 years
- · Controlled turnover
- Ongoing dialogue: 500 meetings/year
- Independence from the benchmark

Risk management

- Financial strength
- · Earning visibility

TEAM

- Resilience to disruption
- Integration of ESG criteria

OBJECTIVE

Placeuro Abacus Discovery (ex - Orion) is a sub-fund of the Placeuro Mutual Fund composed of small-cap stocks from countries in the Eurozone chosen for their fundamental qualities. These "Small/Micro" companies, whose capitalisation does not exceed €2 billion at the time of their acquisition, are selected through a rigorous and transparent process, Abacus, in complete independence from stock market indices. This proprietary methodology allows us to aim for the best risk-adjusted performance. This fund is eligible for PEA and PEA - PME. The benchmark is the Eurostoxx Small NR.



Edwin FAURE Chief Investment Officer Fund Manager



Thomas RICHARD, CFA Fund Manager - Analyst






Romain RIEUL Fund Manager - Analyst

Philippe Hottinguer PLACEURO ABACUS DISCOVERY September 2025

September 2025

COUNTRY BREAKDOWN





Main Stocks	Sector	Weight	Beta 3Y
Arteche	Energetic transtition	5.8%	0.34
Reway Group	Infrastructure	5.1%	0.83
I.CO.P.	Infrastructure	4.8%	-0.98
MS International	Cyber & Defense	4.0%	-0.55
PROFILE Systems	Software	3.6%	0.75

ESG SCORES

	Abacus	Eurostoxx
	Discovery	Small
ESG*	68/100	64/100
Environnemental	36/100	68/100
Social	48/100	49/100
Societal	47/100	60/100
Governance	77/100	80/100

^{*}Adjusted weighted score between each pillars

INDUSTRY BREAKDOWN Energetic transtition Digitalisation Other Infrastructure Software Cyber & Defense ■ Abacus Discovery Supply chain Consumer discretionary Special situations 5%

CAPITALIZATION BREAKDOWN

Intervals	Weight
Less than 100M€	26.2%
Between 100M€ and 300M€	35.0%
Between 300M€ and 1B€	30.8%
Between 1B€ and 2B€	5.9%
More than 2B€	0.0%

Emission footprint

110.3

TCO2/M€ invested

Abacus Discovery

354.0


TCO2/M€ invested

Eurostoxx Small


MAINS CONTRIBUTIONS

Main monthly contributors						
Arteche	+1.4 pt					
DHH	+0.5 pt					
Intellego	-1.3 pt					
Altea Green Power	-0.5 pt					

ESG SCORES DISTRIBUTION



DIRECT CONTRIBUTION





Eligible Share

38.8

%Sales eligible to

the Taxonomy

Abacus Discovery

31.6

%Sales eligible to

the Taxonomy

Eurostoxx Small









INDIRECT CONTRIBUTION

















Calculated on the invested part

STOCK OF THE MONTH: ILPRA (€5.70) - Well-Packaged Prospects

Ilpra is an SME specializing in the design and production of packaging machines for food, cosmetics, and medical applications. The group focuses on manufacturing packaging machinery, with a particular emphasis on tray sealers, fillers, and thermoforming machines, which together cover most of the packaging market. Despite a visibility of around four months on its order book, Ilpra operates in defensive end-markets and benefits from favorable structural trends such as automation, equipment renewal and modernization, and the industrialization of emerging countries.

Owned 70% by the founding and managing family, Ilpra has a strong track record of organic growth, targeted acquisitions, and profitability. The first-half results, published in September, were very solid, showing +29% year-on-year growth, including +21% organic, driven by international markets (which account for 70% of sales). The EBITDA margin, temporarily under pressure at 16% vs. >20% historically, reflects recent acquisitions and investments aimed at developing international operations.

Looking ahead, management is targeting €100 million in revenue within three years (excluding new acquisitions), implying a +12% CAGR, and intends to maintain an EBITDA margin above 20%. Finally, with a 2026 P/E of 7.8x, a 2026 EV/EBIT of 6.6x, and a FCF yield above 10%, we believe the company offers strong potential and highly attractive

valuation levels.



70 M€

	ESG Analysis				
Exclusion poli	Exclusion policy				
ESG Score					
Monitoring of	rsies +++				
EBITDA Margin	20.2%	Net Margin			

		Valuati	ion potent	tial +	++		
		Inhere	nt risk	+	++		
		Market	t risk	+	++		
5%	EV/EBITE	OA 25	5.0x	P/E 25	7.8x		

Portfolio Monitoring

The information included in this document (provided by PHCG, Factset, Quantalys and Morningstar) is not an offer for products, services or a request for the sale of securities or other manageable products. It is only provided for information purposes and is therefore not binding in any manner. Results achieved in the past are no indication for the future. If you need any further information, you can reach us at +33 1 78 91 79 00 or at 58 rue Pierre Charron, 75008 Paris, or else take a look at our leaflet on www.phhgestion.com